References
Br VK, Sarin SK. Acute-on-chronic liver failure: terminology, mechanisms and management. Clin Mol Hepatol. 2023;29:670–89.
Rovegno M, Vera M, Ruiz A, Benitez C. Current concepts in acute liver failure. Ann Hepatol. 2019;18:543–52.
Kumar R, Anand U, Priyadarshi RN. Liver transplantation in acute liver failure: dilemmas and challenges. World J Transpl. 2021;11:187–202.
Fontana RJ, Liou I, Reuben A, Suzuki A, Fiel MI, Lee W, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023;77:1036–65.
Stravitz RT, Fontana RJ, Karvellas C, Durkalski V, McGuire B, Rule JA, et al. Future directions in acute liver failure. Hepatology. 2023;78:1266–89.
Flint RB, Mian P, van der Nagel B, Slijkhuis N, Koch BC. Quantification of acetaminophen and its metabolites in plasma using UPLC-MS: doors open to therapeutic drug monitoring in special patient populations. Ther Drug Monit. 2017;39:164–71.
Chidiac AS, Buckley NA, Noghrehchi F, Cairns R. Paracetamol (acetaminophen) overdose and hepatotoxicity: mechanism, treatment, prevention measures, and estimates of burden of disease. Expert Opin Drug Metab Toxicol. 2023;19:297–317.
Cai X, Cai H, Wang J, Yang Q, Guan J, Deng J, et al. Molecular pathogenesis of acetaminophen-induced liver injury and its treatment options. J Zhejiang Univ Sci B. 2022;23:265–85.
Tian J, Zhang S, Li L, Lin X, Li Y, Zhao K, et al. Febuxostat ameliorates APAP-induced acute liver injury by activating Keap1/Nrf2 and inhibiting TLR4/NF-kappaB p65 pathways. Exp Biol Med (Maywood). 2023;248:1864–76.
Chou AH, Lee HC, Liao CC, Yu HP, Liu FC. ERK/NF-kB/COX-2 signaling pathway plays a key role in curcumin protection against acetaminophen-induced liver injury. Life (Basel) 2023;13:2150.
Shi C, Hao B, Yang Y, Muhammad I, Zhang Y, Chang Y, et al. JNK signaling pathway mediates acetaminophen-induced hepatotoxicity accompanied by changes of glutathione S-transferase A1 content and expression. Front Pharmacol. 2019;10:1092.
Tao J, Xue C, Wang X, Chen H, Liu Q, Jiang C, et al. GAS1 promotes ferroptosis of liver cells in acetaminophen-induced acute liver failure. Int J Med Sci. 2023;20:1616–30.
Yu Y, Chang L, Hu Q, Zhu J, Zhang J, Xia Q, et al. P2rx1 deficiency alleviates acetaminophen-induced acute liver failure by regulating the STING signaling pathway. Cell Biol Toxicol. 2023;39:2761–74.
Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463–8.
Ho MY, Wang CY. Role of irisin in myocardial infarction, heart failure, and cardiac hypertrophy. Cells. 2021;10:2103.
Li DJ, Sun SJ, Fu JT, Ouyang SX, Zhao QJ, Su L, et al. NAD+-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin. Theranostics. 2021;11:4381–402.
Pang Q, Wang P, Pan Y, Dong X, Zhou T, Song X, et al. Irisin protects against vascular calcification by activating autophagy and inhibiting NLRP3-mediated vascular smooth muscle cell pyroptosis in chronic kidney disease. Cell Death Dis. 2022;13:283.
Zhu W, Sahar NE, Javaid HMA, Pak ES, Liang G, Wang Y, et al. Exercise-induced irisin decreases inflammation and improves NAFLD by competitive binding with MD2. Cells. 2021;10:3306.
Bi J, Zhang J, Ren Y, Du Z, Li Q, Wang Y, et al. Irisin alleviates liver ischemia-reperfusion injury by inhibiting excessive mitochondrial fission, promoting mitochondrial biogenesis and decreasing oxidative stress. Redox Biol. 2019;20:296–306.
Gaggini M, Cabiati M, Del Turco S, Navarra T, De Simone P, Filipponi F, et al. Increased FNDC5/Irisin expression in human hepatocellular carcinoma. Peptides. 2017;88:62–6.
Liao X, Luo Y, Gu F, Song W, Nie X, Yang Q. Therapeutic role of FNDC5/irisin in attenuating liver fibrosis via inhibiting release of hepatic stellate cell-derived exosomes. Hepatol Int. 2023;17:1659–71.
Kim H, Wrann CD, Jedrychowski M, Vidoni S, Kitase Y, Nagano K, et al. Irisin mediates effects on bone and fat via alphaV integrin receptors. Cell. 2018;175:1756–68 e17.
Kam TI, Park H, Chou SC, Van Vranken JG, Mittenbuhler MJ, Kim H, et al. Amelioration of pathologic alpha-synuclein-induced Parkinson’s disease by irisin. Proc Natl Acad Sci USA. 2022;119:e2204835119.
Ramachandran A, Jaeschke H. Acetaminophen hepatotoxicity. Semin Liver Dis. 2019;39:221–34.
Wang M, Sun J, Yu T, Wang M, Jin L, Liang S, et al. Diacerein protects liver against APAP-induced injury via targeting JNK and inhibiting JNK-mediated oxidative stress and apoptosis. Biomed Pharmacother. 2022;149:112917.
Zhang X, Zhao Y, Li M, Wang M, Qian J, Wang Z, et al. A synergistic regulation works in matrix stiffness-driven invadopodia formation in HCC. Cancer Lett. 2024;582:216597.
Wang J, Zhao YT, Zhang LX, Dubielecka PM, Qin G, Chin YE, et al. Irisin deficiency exacerbates diet-induced insulin resistance and cardiac dysfunction in type II diabetes in mice. Am J Physiol Cell Physiol. 2023;325:C1085–C96.
Guo M, Yao J, Li J, Zhang J, Wang D, Zuo H, et al. Irisin ameliorates age-associated sarcopenia and metabolic dysfunction. J Cachexia Sarcopenia Muscle. 2023;14:391–405.
Yang BC, Leung PS. Irisin is a positive regulator for ferroptosis in pancreatic cancer. Mol Ther Oncolytics. 2020;18:457–66.
Li RL, Wu SS, Wu Y, Wang XX, Chen HY, Xin JJ, et al. Irisin alleviates pressure overload-induced cardiac hypertrophy by inducing protective autophagy via mTOR-independent activation of the AMPK-ULK1 pathway. J Mol Cell Cardiol. 2018;121:242–55.
Zhong L, Zhao J, Huang L, Liu Y, Pang X, Zhan K, et al. Runx2 activates hepatic stellate cells to promote liver fibrosis via transcriptionally regulating Itgav expression. Clin Transl Med. 2023;13:e1316.
Turaga RC, Satyanarayana G, Sharma M, Yang JJ, Wang S, Liu C, et al. Targeting integrin alphavbeta3 by a rationally designed protein for chronic liver disease treatment. Commun Biol. 2021;4:1087.
Greenhalgh SN, Matchett KP, Taylor RS, Huang K, Li JT, Saeteurn K, et al. Loss of integrin alphavbeta8 in murine hepatocytes accelerates liver regeneration. Am J Pathol. 2019;189:258–71.
Islam MR, Valaris S, Young MF, Haley EB, Luo R, Bond SF, et al. Exercise hormone irisin is a critical regulator of cognitive function. Nat Metab. 2021;3:1058–70.
Grgic J. What is the effect of paracetamol (acetaminophen) ingestion on exercise performance? current findings and future research directions. Sports Med. 2022;52:431–9.
Yu Q, Kou W, Xu X, Zhou S, Luan P, Xu X, et al. FNDC5/Irisin inhibits pathological cardiac hypertrophy. Clin Sci (Lond). 2019;133:611–27.
